Success Metrics

Clinical Success Rate
100.0%

Based on 5 completed trials

Completion Rate
100%(5/5)
Active Trials
0(0%)
Results Posted
20%(1 trials)

Phase Distribution

Ph phase_3
1
20%

Phase Distribution

0

Early Stage

0

Mid Stage

1

Late Stage

Phase Distribution1 total trials
Phase 3Large-scale testing
1(100.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

5 of 5 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

5

all time

Status Distribution
Completed(5)

Detailed Status

Completed5

Development Timeline

Analytics

Development Status

Total Trials
5
Active
0
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 31 (100.0%)

Trials by Status

completed5100%

Recent Activity

0 active trials
Showing 5 of 5
completedphase_3

A Study Comparing the Effects and Safety of Dulaglutide With Insulin Glargine in Type 2 Diabetes Mellitus

NCT01648582
completed

Cardiovascular Outcomes in Participants With Type 2 Diabetes Mellitus (T2DM)

NCT03249506
completed

Incretin-based Drugs and Acute Pancreatitis

NCT02476760
completed

Incretin-based Drugs and the Risk of Heart Failure

NCT02456428
completed

Incretin-based Drugs and Pancreatic Cancer

NCT02475499

Clinical Trials (5)

Showing 5 of 5 trials
NCT01648582Phase 3

A Study Comparing the Effects and Safety of Dulaglutide With Insulin Glargine in Type 2 Diabetes Mellitus

Completed
NCT03249506

Cardiovascular Outcomes in Participants With Type 2 Diabetes Mellitus (T2DM)

Completed
NCT02476760

Incretin-based Drugs and Acute Pancreatitis

Completed
NCT02456428

Incretin-based Drugs and the Risk of Heart Failure

Completed
NCT02475499

Incretin-based Drugs and Pancreatic Cancer

Completed

All 5 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
5